We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $20B
1-Year Est. Return 154.41%
This Fund
S&P 500
This Quarter Est. Return
+0.68%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$10.2B
AUM Growth
-$819M
Cap. Flow
-$1.84B
Cap. Flow %
-18.03%
Top 10 Hldgs %
83.92%
Holding
140
New
7
Increased
13
Reduced
18
Closed
7

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$96.9M
2
ONC
BeOne Medicines Ltd
ONC
+$55.3M
3
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$38.3M
4
AKAO
Achaogen Inc
AKAO
+$30.7M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$16.8M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$773M
2
EXEL icon
Exelixis
EXEL
+$27.8M
3
TGTX icon
TG Therapeutics
TGTX
+$15.5M
4
ARWR icon
Arrowhead Research
ARWR
+$13.6M
5
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 87.85%
2 Miscellaneous 12.14%
3 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRVN
76
DELISTED
Trevena, Inc.
TRVN
$2.65M 0.03%
720
– –
ENTA icon
77
Enanta Pharmaceuticals
ENTA
$382M
$2.52M 0.02%
75,357
– –
SYRS
78
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.49M 0.02%
20,447
– –
OSIR
79
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$2.45M 0.02%
499,193
– –
TRIL
80
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.34M 0.02%
413,697
– –
CBIO
81
Crescent Biopharma
CBIO
$731M
$2.33M 0.02%
3,812
– –
CRBP icon
82
Corbus Pharmaceuticals
CRBP
$156M
$2.2M 0.02%
+8,671
New +$1.99M
NBRV
83
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$2.09M 0.02%
1,400
– –
KPTI icon
84
Karyopharm Therapeutics
KPTI
$36.3M
$2.04M 0.02%
14,466
– –
SYRE icon
85
Spyre Therapeutics
SYRE
$8.01B
$1.76M 0.02%
16,169
– –
FSTX
86
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$1.75M 0.02%
+54,825
New +$2.01M
NVIV
87
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
$1.68M 0.02%
21
– –
CNCE
88
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$1.57M 0.02%
152,964
-164,012
-52% -$1.5M
JUNO
89
DELISTED
Juno Therapeutics, Inc.
JUNO
$1.51M 0.01%
80,000
– –
SCYX icon
90
SCYNEXIS
SCYX
$45.8M
$1.49M 0.01%
5,845
– –
FLGT icon
91
Fulgent Genetics
FLGT
$568M
$1.45M 0.01%
125,000
– –
MYOK
92
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$1.29M 0.01%
100,000
– –
QURE icon
93
uniQure
QURE
$3.12B
$1.29M 0.01%
230,000
– –
MCRB icon
94
Seres Therapeutics
MCRB
$47.5M
$1.24M 0.01%
6,250
– –
CLCD
95
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$1.1M 0.01%
30,310
– –
AIXC
96
AIxCrypto Holdings Inc
AIXC
$25.1M
$1.08M 0.01%
3
– –
PRQR icon
97
ProQR Therapeutics
PRQR
$262M
$1.04M 0.01%
212,698
-647,766
-75% -$3.34M
MDWD icon
98
MediWound
MDWD
$179M
$1.03M 0.01%
32,286
– –
PTN
99
Palatin Technologies
PTN
$23.8M
$1.03M 0.01%
1,640
– –
FPRX
100
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$964K 0.01%
19,247
– –
2 3
4
5 6

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Baker Bros. Advisors's Q4 2016 Portfolio in Review

As of Q4 2016, Baker Bros. Advisors held 140 positions worth $10.2B, down 7.4% from $11B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Baker Bros. Advisors withdrew a net $1.84B in Q4 2016, closing 7 positions and reducing 18 holdings. Its most notable exit was TG Therapeutics, an estimated $15.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Baker Bros. Advisors opened a new position in AveXis, Inc. Common Stock worth $15M.

  • Baker Bros. Advisors's largest Q4 2016 buy was AveXis, Inc. Common Stock: 315,300 shares worth $15M.
  • Baker Bros. Advisors added most to Seagen Inc. Common Stock in Q4 2016, an estimated $96.9M increase.
  • Baker Bros. Advisors's biggest Q4 2016 reduction was AbbVie, cutting an estimated $773M.
  • Baker Bros. Advisors fully exited TG Therapeutics in Q4 2016, selling an estimated $15.5M.
  • Baker Bros. Advisors's ten largest holdings make up 84% of its $10.2B portfolio in Q4 2016.
  • Baker Bros. Advisors opened 7 new positions and closed 7 in Q4 2016.
  • Baker Bros. Advisors's portfolio value fell 7.4% quarter-over-quarter to $10.2B.

Based on Baker Bros. Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.